December 18, 2019

FOCUS ON DME/DR

Is deep learning the future of diabetic retinopathy screening? Deep learning could have an application in the diagnosis and management of retinal diseases. Here’s what clinicians need to know Read on ADVERTISEMENT

Tracking anti-VEGF use among Medicare Part B beneficiaries Anti-VEGF agents have ushered in a new era of treatment for retinal and choroidal neovascularization. Here’s what researchers have learned in determining how these agents have evolved, specifically regarding trends for U.S. Medicare Part B beneficiaries. Learn more